Related Experiment Video

Updated: Sep 16, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

Sorafenib Resistance in Hepatocellular Carcinoma: Emerging Molecular Insights from Long Non-Coding RNAs

Dengke Jia1,2,3, Yaping He4, Qianle Chen1,2,3

  • 1Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.

Current Pharmaceutical Design
|July 10, 2025
PubMed
Abstract

Insights

Long non-coding RNAs (lncRNAs) are key players in hepatocellular carcinoma (HCC) resistance to sorafenib. Understanding lncRNA pathways offers new therapeutic strategies for overcoming drug resistance in HCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sorafenib is a primary treatment for advanced hepatocellular carcinoma (HCC).
  • Drug resistance significantly limits sorafenib's effectiveness in HCC treatment.
  • The role of long non-coding RNAs (lncRNAs) in HCC sorafenib resistance is not fully understood.

Purpose of the Study:

  • To review recent findings on pathways involved in sorafenib resistance in HCC.
  • To explore the potential of lncRNAs as therapeutic targets for HCC treatment.

Main Methods:

  • Literature search of relevant studies on PubMed.
  • Analysis of research papers on lncRNA and sorafenib resistance in HCC from the past decade.

Main Results:

  • lncRNAs are extensively implicated in HCC resistance to sorafenib.
  • Specific lncRNAs, like NEAT1, influence HCC sensitivity via pathways such as autophagy and AKT signaling.

Conclusions:

  • lncRNAs are crucial in regulating HCC resistance to sorafenib.
  • lncRNAs show promise as novel therapeutic targets for overcoming resistance to sorafenib and other drugs.
Keywords:
Long non-coding RNAsbiomolecular marker.drug resistancehepatocellular carcinomamicroRNAssorafenib

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K